CPI-003 is Curadel’s lead zwitterionic targeted alpha therapy. It is focused initially in metastatic cancer, which has high unmet needs. Multiple targeting ligands are added to its zwitterionic backbone to bind to tumors quickly after intravenous injection, avoid normal tissues and organs, and clear rapidly from the body via renal filtration and elimination into urine. Rapid and specific binding, clearance, and cell kill creates a huge therapeutic window and heralds improvement of TAT therapy that is generations ahead of current and emerging market options.

Strong Zwitterionic chelation for combination with monoclonal antibodies with no impact on pharmacokinetics, tumor targeting or safety

• Curadel’s first zwitterionic imaging drug ZW800-1, also known as nizaracianine triflutate, was the world’s first zwitterionic NIR fluorophore. It is used by surgeons to identify and avoid the ureters in real-time during abdominopelvic surgery to avoid damage, which often results in significant morbidity and occasionally mortality. ZW800-1 is the subject of an exclusive distribution agreement with a Tier 1 medical device company and is currently undergoing its pivotal trial.
• Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery (TRIPHASE)(NCT06101745)

Integrin-targeted zwitterionic ICG analog, initially focused on pancreatic, biliary, head & neck resection.

Novel zwitterionic chelator for MRI with best-in-class relaxivity and minimal retention.